Screener
Tango Therapeutics TNGX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest income | 2,177 | 1,614 |
| Other income, net | 1,079 | 1,074 |
| Total other income, net | 3,256 | 2,688 |
| Loss before income taxes | (45,513) | (39,842) |
| Provision for income taxes | (1) | (34) |
| Net loss | $(45,514) | $(39,876) |
| Net loss per common share – basic and diluted | $(0.32) | $(0.36) |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's other income (expense)?
- Tango Therapeutics (TNGX) reported other income (expense) of $3.26M in Q1 2026.
- How has Tango Therapeutics's other income (expense) changed year-over-year?
- Tango Therapeutics's other income (expense) increased by 21.1% year-over-year, from $2.69M to $3.26M.
- What is the long-term trend for Tango Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Tango Therapeutics's other income (expense) has grown at a 150.3% compound annual growth rate (CAGR), from $247K to $9.7M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Tango Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude